News

Mirim-Zine

  • PCMO and MirimGENE begin development of ‘WARS1’ targeted Tuberculosis treatment

    July 17, 2024

    PCMO (Public CDMO for Microbial-based Vaccines, Director Min Cho) and MirimGENE Co., Ltd. (CEO Mirim Jin) are co-developing a ' Recombinant protein therapy for Tuberculosis' based on the innovative drug platform targeting WARS1(Tryptophanyl- tRNA synthetase 1) and announced this on July 16.   source: https://www.yakup.com/news/index.html?mode=view&pmode=&cat=&cat2=&...

    READ MORE >
  • Professor Mirim Jin of Gachon University College of Medicine won the 34th Science and Technology Outstanding Paper Award in 2024

    July 16, 2024

    가천대 의과대학 진미림 교수가 제2회 세계 한인 과학기술인 대회에서 한국과학기술단체총연합회가 수여하는 보건의료분야 과학기술 우수논문상을 수상했다.  진미림 교수는 한국응용약물학회에서 발간하는 Biomolecules & Therapeutics 저널에 게재한 “Phytochemicals That Act on Synaptic Plasticit...

    READ MORE >
  • “㈜미림진, ㈜보령과 혁신신약 개발분야 업무 협약(MOU) 체결” / MirimGENE and BORYUNG signed an MOU in the field for innovative new drug development

    March 13, 2024

    ㈜미림진(대표 진미림)은 ㈜보령(대표 장두현)과 혁신신약 개발 분야 업무제휴 협약(MOU)을 체결했다고 13일 밝혔다.   ㈜미림진과 ㈜보령은 이번 전략적 업무 제휴를 바탕으로 난치성 면역 질환 혁신 신약과 제약산업 경쟁력 강화를 위해 양사의 협력을 도모할 예정이다.    &...

    READ MORE >
  • 미림진, 패혈증 테라노스틱스 연구결과 글로벌 학술지 게재 / MirimGENE, Sepsis Theranostics research results published in global academic journals

    December 18, 2023

    We expect to present an innovative alternative that can increase the survival rate of septic shock.” Mirim Jin (CEO MirimGENE) announced on the 18th that the results of sepsis theranostics targeting WARS1 were published in the world-renowned medical journal 'EMBO Molecular Medicine (IF=14.005)' (title: 'Highly secreted tryptophanyl-tRNA synthetase as...

    READ MORE >
  • 미림진, 진미림 대표 여성생명과학기술포럼 심포지엄 강연 / MirimGENE’ CEO, 22nd Women’s Bioscience Forum Symposium Presentation

    September 21, 2023

    Dr. Mirim Jin, the CEO, was in attendance at the Women’s Bioscience Forum (WBF) Symposium (22nd), which took place on September 21st, and delivered a presentation.   

    READ MORE >
  • 미림진, "WARS1 타깃 자가면역질환 치료제 개발…내년 하반기 비임상 진입" / MirimGENE "Development of WARS1-targeted autoimmune disease therapy, launch of pre-clinical trials in the second half of next year."

    August 17, 2023

    CEO Mirim Jin conducted an interview with HitNews on the topic of “MirimGENE's core pipeline status and future blueprint.""We will leap forward as a biotech that leads the development of innovative new drugs (first-in-class) that can save the lives of autoimmune disease patients around the world. Currently, the manufacturing process (CMC) stage of the lead pipeline (new drug candida...

    READ MORE >